AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board
AC Immune (NASDAQ: ACIU) appointed Prof. Catherine Mummery as Chair of its Clinical Advisory Board effective October 28, 2025.
Prof. Mummery leads cognitive disorders at NHNN and novel therapeutics at UCL, has been senior investigator on more than 20 early-stage studies, led the first clinical trial of a Tau gene‑silencing therapy, and served as an investigator on AC Immune’s Phase 1b/2a ACI-35.030 (JNJ-2056) study.
The CAB advises on clinical development and regulatory strategy; other members include Reisa Sperling, Murat Emre, Lon Schneider, Pierre Tariot, and Juan Fortea. Dr. Kaj Blennow is retiring from the CAB.
AC Immune (NASDAQ: ACIU) ha nominato la prof.ssa Catherine Mummery come presidente del suo Clinical Advisory Board con effetto dal 28 ottobre 2025.
La prof.ssa Mummery guida i disturbi cognitivi al NHNN e i nuovi terapeuti presso UCL; è stata ricercatrice senior in più di 20 studi in fase iniziale, ha guidato la prima trial clinica di una terapia di silenziamento genico del Tau, e ha lavorato come investigatrice nello studio AC Immune’s Phase 1b/2a ACI-35.030 (JNJ-2056).
Il CAB fornisce consulenza su sviluppo clinico e strategia regolatoria; tra gli altri membri ci sono Reisa Sperling, Murat Emre, Lon Schneider, Pierre Tariot e Juan Fortea. Il Dr. Kaj Blennow si ritira dal CAB.
AC Immune (NASDAQ: ACIU) nombró a la profesora Catherine Mummery como presidenta de su Clinical Advisory Board con efecto a partir del 28 de octubre de 2025.
La profesora Mummery dirige los trastornos cognitivos en el NHNN y terapias novedosas en la UCL; ha sido investigadora principal en más de 20 estudios en fases tempranas, dirigió la primera prueba clínica de una terapia de silenciamiento génico de Tau, y ha participado como investigadora en el estudio AC Immune de Fase 1b/2a ACI-35.030 (JNJ-2056).
El CAB asesora sobre desarrollo clínico y estrategia regulatoria; otros miembros incluyen Reisa Sperling, Murat Emre, Lon Schneider, Pierre Tariot y Juan Fortea. El Dr. Kaj Blennow se retira del CAB.
AC Immune (NASDAQ: ACIU)는 2025년 10월 28일부터 임상 자문위원회(CAB)의 의장으로 카트린 뭄멜리 교수님을 임명했습니다.
뭄멜리 교수님은 NHNN의 인지장애 연구를 이끌고 UCL의 신규 치료제 개발을 담당하며, 20건이 넘는 초기 연구를 선임 연구원으로 수행했고 타우(Tau) 유전자 침묵 치료의 첫 임상시험을 주도했으며 AC Immune의 Phase 1b/2a ACI-35.030 (JNJ-2056) 연구의 연구원으로도 활동했습니다.
CAB은 임상 개발 및 규제 전략에 대한 조언을 제공하며, 다른 구성원으로는 Reisa Sperling, Murat Emre, Lon Schneider, Pierre Tariot, Juan Fortea가 있습니다. Dr. Kaj Blennow은 CAB에서 은퇴합니다.
AC Immune (NASDAQ: ACIU) a nommé la professeure Catherine Mummery comme présidente de son Clinical Advisory Board à compter du 28 octobre 2025.
La professeure Mummery dirige les troubles cognitifs au NHNN et les thérapies innovantes à l'UCL; elle a été investigatrice principale sur plus de 20 études en phase précoce, a dirigé la première étude clinique d'une thérapie d'extinction génique du Tau et a agi en tant qu'enquêteur dans l'étude AC Immune de phase 1b/2a ACI-35.030 (JNJ-2056).
Le CAB conseille sur le développement clinique et la stratégie réglementaire; les autres membres incluent Reisa Sperling, Murat Emre, Lon Schneider, Pierre Tariot et Juan Fortea. Le Dr Kaj Blennow se retire du CAB.
AC Immune (NASDAQ: ACIU) hat Prof. Catherine Mummery mit Wirkung zum 28. Oktober 2025 zur Vorsitzenden des Clinical Advisory Board ernannt.
Prof. Mummery leitet kognitive Störungen am NHNN und neue Therapeutika an der UCL; sie war leitende Forscherin in mehr als 20 Frühphasenstudien, leitete die erste klinische Studie einer Tau-Gen-Silencing-Therapie und war als Prüferin an der AC Immune-Phase-1b/2a-Studie ACI-35.030 (JNJ-2056) beteiligt.
Das CAB berät in klinischer Entwicklung und regulatorischer Strategie; weitere Mitglieder sind Reisa Sperling, Murat Emre, Lon Schneider, Pierre Tariot und Juan Fortea. Dr. Kaj Blennow zieht sich aus dem CAB zurück.
AC Immune (NASDAQ: ACIU) عينت البروفيسورة كاثرين موميري رئيسة المجلس الاستشاري الطبي السريري اعتباراً من 28 أكتوبر 2025.
تدير البروفيسورة موميري اضطرابات الإدراك في NHNN وتطوير العلاجات الجديدة في UCL، وكانت باحثة رئيسية في أكثر من 20 دراسة مبكرة، وأدارت أول تجربة سريرية لعلاج كبح جيني لتاو، وشاركت ككاتبة باحثة في دراسة AC Immune للمرحلة 1b/2a ACI-35.030 (JNJ-2056).
المجلس الاستشاري الطبي السريري يقدم المشورة في التطوير العلاجي والاستراتيجية التنظيمية؛ من أعضائه الآخرين ريـسـا سبيرلنغ، موراة إمري، لون شنايدر، بيير تاريوت، وخوان فورتا. الدكتور كاج بلينوو يتقاعد من المجلس.
AC Immune (NASDAQ: ACIU) 任命 Catherine Mummery 教授为其临床咨询委员会（CAB）主席，自 2025 年 10 月 28 日起生效。
Mummery 教授在 NHNN 领导认知疾病研究，在 UCL 负责新型治疗方案；她曾作为高级研究员参与 超过 20 项早期研究，领导了 tau 基因沉默疗法的第一项临床试验，并担任 AC Immune 的 1b/2a 期 ACI-35.030（JNJ-2056）研究的研究人员。
CAB 为临床发展和监管策略提供建议；其他成员包括 Reisa Sperling、Murat Emre、Lon Schneider、Pierre Tariot 和 Juan Fortea。Dr. Kaj Blennow 将从 CAB 退休。
- Three active immunotherapies in Phase 2 development
- Prof Mummery: senior investigator on >20 early-stage dementia studies
- Investigator on the Phase 1b/2a trial of ACI-35.030 (JNJ-2056)
- Experience leading first-ever clinical trial of a Tau gene‑silencing therapy
- None.
AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board
- Brings substantial expertise in development of first-in-class disease-modifying therapies in dementia across multiple novel modalities
- Includes immunotherapies and small molecule drugs targeting intracellular proteinopathies
- Leadership in groundbreaking early-stage clinical trials reinforces Company’s competencies
Lausanne, Switzerland, October 28, 2025 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced the appointment of Prof. Catherine Mummery, a deeply experienced neurologist and expert in dementia clinical trials, as Chairwoman of its Clinical Advisory Board (CAB).
Prof. Mummery leads the cognitive disorders service at the UK’s National Hospital for Neurology and Neurosurgery (NHNN), where she has practiced as a consultant neurologist since 2004. She is head of novel therapeutics at the Dementia Research Centre at University College London (UCL), and deputy director for the Leonard Wolfson Experimental Neurology Centre at NHNN, a unit dedicated to early phase trials in neurodegeneration.
She has been senior investigator on more than 20 early-stage studies of disease-modifying agents in dementias, including the first-ever clinical trial of a gene silencing therapy targeting Tau to treat Alzheimer’s disease, as well as trials of AC Immune’s anti-pTau active immunotherapy candidate ACI-35.030 (JNJ-2056).
Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “It is a great honor that Prof. Mummery has accepted to lead our Clinical Advisory Board. As an investigator on the recently published Phase 1b/2a trial of ACI-35.030 (JNJ-2056), Catherine has been instrumental in the progress we have achieved with our SupraAntigen® immunotherapies. This appointment will now extend her involvement across our entire pipeline of precision prevention candidates, including our three active immunotherapies in Phase 2 development and our most exciting novel therapeutics targeting intracellular mechanisms of neurodegenerative diseases that are approaching the clinic, including ACI-19764 targeting NLRP3, our Morphomer® Tau program, and our Morphomer® a-syn program.”
Prof. Catherine Mummery, Chair of AC Immune’s Clinical Advisory Board, added: “AC Immune is a leader in the development of precision prevention approaches for neurodegenerative diseases, and I am excited by the opportunity to lead its Clinical Advisory Board. I am looking forward to working with and advising the Company’s talented team as its pipeline of active immunotherapies nears meaningful inflection points in clinical trials, plus a series of first-in-class small molecules that enable intracellular targeting of pathologic proteins moving toward the clinic.”
The CAB provides AC Immune with strategic clinical development and regulatory advice and members are selected based on their expertise and peer recognition in the field of neurodegeneration.
As well as Prof. Mummery, the CAB also includes: Dr. Reisa Sperling, Brigham and Women's Hospital and Massachusetts General Hospital, Boston (US); Dr. Murat Emre, Istanbul Faculty of Medicine, Istanbul University, Istanbul (Turkey); Dr. Lon Schneider, Keck School of Medicine of University of Southern California, Los Angeles, CA (US); Dr. Pierre Tariot, Banner Alzheimer’s Institute, Phoenix, AZ (US); and Dr. Juan Fortea, Hospital of Sant Pau, Barcelona (Spain).
Dr. Kaj Blennow, the previous Chairman, is retiring from the CAB. AC Immune thanks Dr. Blennow for his support and invaluable guidance.
About AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company and a global leader in precision prevention for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen® and Morphomer®, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features a range of therapeutic and diagnostic programs, including candidates in Phase 2 and Phase 3 development. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies, resulting in substantial non-dilutive funding to advance its proprietary programs and >
SupraAntigen® is a registered trademark of AC Immune SA in the following territories: AU, EU, CH, GB, JP, RU, SG and USA. Morphomer® is a registered trademark of AC Immune SA in CN, CH, EU, GB, JP, KR, NO, RU and SG.
The information on our website and any other websites referenced herein is expressly not incorporated by reference into, and does not constitute a part of, this press release.
For further information, please contact:
| SVP, Investor Relations & Corporate Communications Gary Waanders, Ph.D., MBA AC Immune Phone: +41 21 345 91 91 Email: gary.waanders@acimmune.com | |
| International Media Chris Maggos Cohesion Bureau Phone: +41 79 367 6254 Email: chris.maggos@cohesionbureau.com |
Forward looking statements
This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.
Attachment
FAQ
Who is the new Chair of AC Immune's Clinical Advisory Board (ACIU) and when was she appointed?
What clinical experience does Prof. Catherine Mummery bring to AC Immune (ACIU)?
How is Prof. Mummery connected to AC Immune’s ACI-35.030 program (ACIU)?
Which AC Immune (ACIU) programs did the announcement highlight as nearing the clinic?
Who are other members of AC Immune’s Clinical Advisory Board (ACIU)?
What change occurred to the CAB leadership at AC Immune (ACIU)?
